AMGN Amgen
- 312.860
- +5.550+1.81%
- 313.400
- +0.540+0.17%
Amgen News
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:20 a.m. PT on Tuesday, May 14, 2024. Peter...
Why the Dow Keeps Outperforming the S&P 500 This Month
The Dow Jones Industrial Average has closed higher every day in May, beating out the S&P 500 for a rare stretch.
Trade Desk To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Baird raise
Amgen Is Maintained at Neutral by Mizuho
Amgen Is Maintained at Neutral by Mizuho
Mizuho Bank: Maintaining the Amgen (AMGN.US) rating, adjusted from neutral to neutral, and adjusted the target price from $223.00 to $235.00.
Mizuho Bank: Maintaining the Amgen (AMGN.US) rating, adjusted from neutral to neutral, and adjusted the target price from $223.00 to $235.00.
Mizuho Maintains Neutral on Amgen, Raises Price Target to $235
Mizuho analyst Salim Syed maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $223 to $235.
Amgen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 -23.57% Mizuho $223 → $235 Maintains Neutral 05/03/2024 6.67% RBC Capital $332 → $328 Maintains
Redburn Atlantic Adjusts Price Target on Amgen to $180 From $170
Amgen (AMGN) has an average outperform rating and a price target range of $170 to $380, according to analysts polled by Capital IQ.
Mizuho Securities Raises Amgen's Price Target to $235 From $223
Amgen (AMGN) has an average outperform rating and a price target range of $170 to $380, according to analysts polled by Capital IQ. Price: 304.24, Change: +3.94, Percent Change: +1.31
Market Whales and Their Recent Bets on AMGN Options
Whales with a lot of money to spend have taken a noticeably bearish stance on Amgen.Looking at options history for Amgen (NASDAQ:AMGN) we detected 17 trades.If we consider the specifics of each trade,
Is the “Nolly” monopoly myth changing? Pharmaceutical companies frequently introduce new drugs, and “weight loss duos” face challenges
Novo Nordisk and Eli Lilly's dominance in the emerging diet medicine market could eventually be threatened by strong rivals.
15 Best S&P 500 Dividend Stocks To Buy Now
How Is The Market Feeling About Amgen?
Amgen's (NYSE:AMGN) short percent of float has fallen 3.57% since its last report. The company recently reported that it has 10.11 million shares sold short, which is 1.89% of all regular shares that
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
US Stock Nuggets | Is liquid cooling a must for AI? Nvidia's exclusive liquid cooling supplier Vertiv's stock price doubled during the year
Is electricity at the end of AI? US power engineering contractor Guangda Service has increased more than 6 times in 5 years; rushing ahead of performance? Neighboring countries rose more than 3% overnight, and their market capitalization was above 10 billion US dollars.
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday.Shares of Spirit Airlines, Inc. (NYSE:SAVE) fell sharply during Monday's session as the company reported a first-qu
CytomX Raised to Buy at Jefferies in Anticipation of Phase 1 Solid Tumors Asset Data
Amgen CEO Robert Bradway, On Innovation In Healthcare, Says "Hoping To Have Innovation Approved For Small Cell Lung Cancer"; "We Hope To Help Rewrite The Understanding Of Obesity And The Diseases That Are Caused By It"
Amgen CEO Robert Bradway, On Innovation In Healthcare, Says "Hoping To Have Innovation Approved For Small Cell Lung Cancer"; "We Hope To Help Rewrite The Understanding Of Obesity And The Diseases That
Dividends Aren't Just for Slow-Growth Stocks
Apple boosted its dividend, and Meta, Alphabet, and Booking all initiated dividends this year. It's all the rage for cash-rich companies.
Amgen Down Over 13%, Worst Performer in the DJIA and Nasdaq 100 So Far Today -- Data Talk
Amgen Inc. (AMGN) is currently at $298.03, down $13.26 or 4.26% --On pace for largest percent decrease since Feb. 7, 2024, when it fell 6.39% --Snaps a three day winning streak --Up 3.48% year-to-d
Analysis
Price Target
No Data
